Table 3.

Comparison of the incidence of adverse events of any grade in patients treated with lenvatinib vs. those treated with sorafenib.

Adverse events N = 71	Lenvatinib N = 23 n (%)	Sorafenib N = 48 n (%)	P-value
Hand-foot skin reaction	13 (56.5)	42 (87.5)	0.003
Diarrhea	19 (82.6)	30 (62.5)	0.086
Alopecia	6 (26.1)	27 (56.3)	0.017
Rash	2 (8.7)	17 (35.4)	0.017
Mucositis	29 (39.1)	25 (52.1)	0.307
Hypertension	18 (78.3)	21 (43.8)	0.006
QT prolongation	2 (8.7)	0	0.038
Generalized weakness	9 (39.1)	24 (50)	0.390
Headache	1 (4.3)	5 (10.4)	0.390
Leucopenia	0	4 (8.3)	0.154
Anemia	1 (4.3)	4 (8.3)	0.539
Hepatitis	0	1 (2.1)	0.486
Anorexia	10 (43.5)	29 (60.4)	0.179
Weight loss	12 (52.2)	24 (50.0)	0.864
Cerebrovascular accident	1 (4.3)	2 (4.2)	0.972
Renal impairment	2 (8.7)	1 (2.1)	0.195
Proteinuria	11 (47.8)	0	<0.001